Exploring the therapeutic mechanisms of Sijunzi decoction in the treatment of sarcopenia: Key targets and signaling pathways

Abstract

AbstractSarcopenia, an age‐associated condition, negatively impacts the quality of life. This study investigates the mechanism of Sijunzi decoction (SJZD), a traditional Chinese formula, against sarcopenia. Active compounds and potential targets of SJZD for sarcopenia were gathered from databases. Hub targets were identified using protein–protein interaction networks, with GO and KEGG analyses suggesting potential pathways. Molecular docking was used to assess compound–target affinity. A lipopolysaccharide‐induced sarcopenia rat model was used to verify the targets. Sijunzi decoction contains 92 compounds and 47 targets for sarcopenia. The top 10 hub targets comprise AKT1, ALB, INS, IL6, TNF, TP53, VEGFA, SIRT1, CAT and FOS. GO and KEGG analyses indicate involvement in steroid hormone response, vesicle lumen, receptor agonist activity, and FoxO and HIF‐1 signaling pathways. Validation experiments showed that SJZD alleviates sarcopenia by downregulating SIRT1, IL‐6, TNF and AKT1. Sijunzi decoction treats sarcopenia by targeting SIRT1, IL‐6, TNF and AKT1, potentially involving FoxO and HIF‐1 signaling pathways. This highlights SJZD’s potential for sarcopenia treatment.